These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16170240)

  • 21. Ashkenazi Jewish population screening for Tay-Sachs disease: the international and Australian experience.
    Lew RM; Burnett L; Proos AL; Barlow-Stewart K; Delatycki MB; Bankier A; Aizenberg H; Field MJ; Berman Y; Fleischer R; Fietz M
    J Paediatr Child Health; 2015 Mar; 51(3):271-9. PubMed ID: 24923490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for genetic disorders among Jews: how should the Tay-Sachs screening program be continued?
    Zlotogora J; Leventhal A
    Isr Med Assoc J; 2000 Sep; 2(9):665-7. PubMed ID: 11062764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carrier testing for autosomal-recessive disorders.
    Vallance H; Ford J
    Crit Rev Clin Lab Sci; 2003 Aug; 40(4):473-97. PubMed ID: 14582604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population-based carrier screening and prenatal diagnosis.
    Strom CM
    MLO Med Lab Obs; 2004 Aug; 36(8):12-7; quiz 20-1. PubMed ID: 15366363
    [No Abstract]   [Full Text] [Related]  

  • 25. Tay-Sachs disease carrier screening: a 21-year experience.
    D'Souza G; McCann CL; Hedrick J; Fairley C; Nagel HL; Kushner JD; Kessel R
    Genet Test; 2000; 4(3):257-63. PubMed ID: 11142756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterozygote carrier testing in high schools abroad: what are the lessons for the U.S.?
    Ross LF
    J Law Med Ethics; 2006; 34(4):753-64. PubMed ID: 17199818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Committee Opinion No. 691: Carrier Screening for Genetic Conditions.
    Obstet Gynecol; 2017 Mar; 129(3):e41-e55. PubMed ID: 28225426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic screening: triumphs, problems, and controversies.
    Natowicz MR; Alper JS
    J Public Health Policy; 1991; 12(4):475-91. PubMed ID: 1802891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. International perspectives on the implementation of reproductive carrier screening.
    Delatycki MB; Alkuraya F; Archibald A; Castellani C; Cornel M; Grody WW; Henneman L; Ioannides AS; Kirk E; Laing N; Lucassen A; Massie J; Schuurmans J; Thong MK; van Langen I; Zlotogora J
    Prenat Diagn; 2020 Feb; 40(3):301-310. PubMed ID: 31774570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carrier screening panels for Ashkenazi Jews: is more better?
    Leib JR; Gollust SE; Hull SC; Wilfond BS
    Genet Med; 2005 Mar; 7(3):185-90. PubMed ID: 15775754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cost-effectiveness of prenatal carrier screening for cystic fibrosis.
    Lieu TA; Watson SE; Washington AE
    Obstet Gynecol; 1994 Dec; 84(6):903-12. PubMed ID: 7970468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Costs, effects, and savings of screening for cystic fibrosis gene carriers.
    Wildhagen MF; Hilderink HB; Verzijl JG; Verheij JB; Kooij L; Tijmstra T; ten Kate LP; Habbema JD
    J Epidemiol Community Health; 1998 Jul; 52(7):459-67. PubMed ID: 9799881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a Tay-Sachs disease screening program.
    Gason AA; Sheffield E; Bankier A; Aitken MA; Metcalfe S; Barlow Stewart K; Delatycki MB
    Clin Genet; 2003 May; 63(5):386-92. PubMed ID: 12752571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pseudodeficiency allele common in non-Jewish Tay-Sachs carriers: implications for carrier screening.
    Triggs-Raine BL; Mules EH; Kaback MM; Lim-Steele JS; Dowling CE; Akerman BR; Natowicz MR; Grebner EE; Navon R; Welch JP
    Am J Hum Genet; 1992 Oct; 51(4):793-801. PubMed ID: 1384323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population screening for reproductive risk for single gene disorders in Australia: now and the future.
    Delatycki MB
    Twin Res Hum Genet; 2008 Aug; 11(4):422-30. PubMed ID: 18637742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variables that underlie cost efficacy of prenatal screening.
    Kinzler WL; Morrell K; Vintzileos AM
    Obstet Gynecol Clin North Am; 2002 Jun; 29(2):277-86, v-vi. PubMed ID: 12108828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of carrier screening for cystic fibrosis in Australia.
    Norman R; van Gool K; Hall J; Delatycki M; Massie J
    J Cyst Fibros; 2012 Jul; 11(4):281-7. PubMed ID: 22425241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tay-Sachs disease--carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. The International TSD Data Collection Network.
    Kaback M; Lim-Steele J; Dabholkar D; Brown D; Levy N; Zeiger K
    JAMA; 1993 Nov; 270(19):2307-15. PubMed ID: 8230592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Tay-Sachs disease gene in North American Jewish populations: geographic variations and origin.
    Petersen GM; Rotter JI; Cantor RM; Field LL; Greenwald S; Lim JS; Roy C; Schoenfeld V; Lowden JA; Kaback MM
    Am J Hum Genet; 1983 Nov; 35(6):1258-69. PubMed ID: 6650504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic Carrier Screening in the Twenty-first Century.
    Yao R; Goetzinger KR
    Clin Lab Med; 2016 Jun; 36(2):277-88. PubMed ID: 27235912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.